Dietary Nitrate, Vascular Function and Inflammation

Effects of Dietary Nitrate on Vascular Function, Blood Pressure, the Oral Microbiome, and Biomarkers of Systemic Inflammation in Hypertensive Older Adults: a Randomized, Placebo-controlled Crossover Study

The risk for cardiovascular diseases (CVD) increases with advancing age. Developing effective lifestyle-based strategies to promote, preserve or restore cardiovascular health with aging is a high priority. The overall aim of this clinical research is to investigate the innovative concept that an increased intake of dietary nitrate (through beetroot juice) could be a feasible adjuvant therapy to treat elevated blood pressure and improve blood vessel function in older adults.

Inorganic dietary nitrate, found in beetroot and green leafy vegetables, is a source of nitric oxide (NO), a signaling molecule that is important for cardiovascular health. NO is also produced in the human body, but the body's production and availability of NO decrease during ageing and CVD. The declined NO availability is associated with impaired blood vessel function, unresolved inflammatory responses, and an increased CVD risk. Dietary nitrate is an additional NO source. Following the intake of nitrate, NO is produced in a pathway that involves commensal bacteria in the mouth. So far, little is known about whether dietary nitrate improves cardiovascular health in older populations with high blood pressure.

The aim of this randomized, placebo-controlled crossover study is to investigate whether the daily intake of nitrate-rich beetroot juice over four weeks translates into improved cardiovascular health-related outcomes in older adults with treated mild high blood pressure. Men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 high blood pressure and who are taking two or more blood-pressure lowering medications will be recruited. The study will investigate whether the increased dietary nitrate intake further lowers blood pressure and improves blood vessel function. A specific aim is to examine whether the nitrate intake results in favorable changes in the oral bacteria community and the systemic inflammatory status, and whether these changes correlate with cardiovascular-related outcomes. This research will offer information on the value of dietary nitrate to counteract chronic inflammation, the latter of which plays a role in developing or worsening cardiovascular disorders, such as high blood pressure.

The expected results of this study will provide important new evidence of whether nitrate-rich beetroot juice could be a key component of therapeutic interventions to improve cardiovascular health in individuals with high blood pressure.

Study Overview

• Status: Completed
• Conditions: Inflammation; Hypertension
• Intervention / Treatment: Dietary supplement: High-nitrate intervention; Dietary supplement: Low-nitrate intervention

Detailed Description

This clinical research is funded by the Austrian Science Fund (FWF, project number: KLI 858). It is based on close collaborations between the University of Vienna and the Medical University of Vienna, with the Department of Clinical Pharmacology at the Medical University of Vienna as the clinical trial center and Prof. M.D. Michael Wolzt as the trial center's coordinating physician. The sponsor is the University of Vienna, as represented by the Principal Investigator Dr. Oliver Neubauer (Research Platform Active Ageing). International collaborations include Dr. Catherine Bondonno, Prof. Hodgson (both Edith Cowan University) Dr. Jonathan Peake (Queensland University of Technology), and Prof. Richard Woodman (Flinders University) (all Australia).

Wider research context / theoretical framework:

Aging is a major risk factor for cardiovascular disease (CVD). Developing effective strategies to improve cardiovascular health with ageing is a high priority. Emerging data indicate that inorganic dietary nitrate, found in green leafy vegetables and beetroot juice (BRJ), is important for cardiovascular health (Blekkenhorst et al. 2018). These data suggest that small increases in nitrate intake among those with elevated risk for CVD would have a substantial impact, by improving the bioavailability of nitric oxide (NO) through the enterosalivary nitrate- nitrite-NO pathway (involving the oral microbiome). Results from the study group's research suggest beneficial short-term effects of nitrate-rich BRJ on blood pressure and vascular inflammation markers in healthy older adults (Raubenheimer et al. 2017).

Hypotheses / research questions / objectives:

The proposed clinical study is aimed to examine whether the daily consumption of 2×70 mL BRJ over 4 weeks translates into improved clinical outcomes in older adults with treated grade 1 hypertension. The primary hypothesis is that the increased dietary nitrate intake lowers blood pressure and improves vascular function. The secondary hypotheses are that the increased dietary nitrate intake results in changes in the oral microbiome, favorably modulates the systemic inflammatory status, and that these changes correlate with cardiovascular-related outcomes.

Approach / methods:

This randomized, placebo-controlled crossover study will involve two 4-week treatment periods, consisting of interventions with nitrate-rich BRJ and nitrate-depleted BRJ, separated by a 4-week washout period. Thirty-five men and women, between the ages of 55 and 70 years, who have been diagnosed with grade 1 hypertension will be recruited. Twenty-nine participants will be required to complete the study, based on power/sample size calculations with the forearm blood flow (FBF) response to acetylcholine and 24 h-ambulatory systolic blood pressure as the primary endpoints. Principal secondary endpoints are the number of CD11b-expressing blood granulocytes and the FBF response to glyceryltrinitrate. Among various additional secondary and exploratory endpoints, plasma nitrate and nitrite and a broad range of inflammation biomarkers will be measured. Furthermore, the oral microbiome will be analyzed.

Level of originality / innovation:

Beneficial effects of nitrate have predominantly been observed in healthy populations, but evidence of cardiovascular benefits and anti-inflammatory effects in clinical populations is limited (Raubenheimer et al. 2019). This study addresses the need to determine the efficacy of dietary nitrate to improve cardiovascular health and counteract chronic low-grade inflammation in humans at risk of CVD.

• Study Type: Interventional
• Enrollment (Actual): 20
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Oliver Neubauer, Dr PhD, PD; Phone Number: 54931 +43-1-4277; Email: oliver.neubauer@univie.ac.at
• Study Contact Backup: Name: Karl-Heinz Wagner, Univ.-Prof.; Phone Number: 54930 +431-4277; Email: karl-heinz.wagner@univie.ac.at

Study Locations

• Austria
  • Vienna, Austria, 1090
    • Medical University of Vienna
  • Vienna, Austria, 1090
    • University of Vienna

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 55 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Ambulant male and females between 55 and 75 years of age, inclusive
• Resting systolic blood pressure between 130 and 170 mmHg, inclusive
• Written informed consent

Exclusion Criteria:

• Diastolic blood pressure >110 mmHg
• Type 1 or 2 diabetes mellitus or fasting glucose >7.0 mmol/L
• Any evidence of acute or chronic disease such as symptomatic cardiovascular or peripheral vascular disease, moderate or severe chronic kidney disease (estimated glomerular filtration rate (GFR) <50 ml/min)), or cancer which is not in remission
• Consumption of ≥5 serves of vegetables per day
• Consumption of a diet estimated to contain >200 mg/d of nitrate
• Being vegan or vegetarian
• BMI ≥35 kg/m2 or <18.5 kg/m2
• Use of nitric oxide donors, organic nitrites/nitrates, sildenafil and related drugs, anti-coagulation, non-steroidal anti-inflammatory or statin-related drugs
• Use of antibacterial mouthwash (volunteers willing to cease using antibacterial mouth wash for a period of 4 weeks before randomisation will be included)
• Use of antibiotics (within previous 2 months)
• A change in drug therapy likely to influence blood pressure or major secondary outcomes within the previous month, or the likelihood that drug therapy would change during the study
• Current or recent (within previous 3 months) engagement in regular structured exercise training (more than 2 hours of moderate to more intense exercise per week)
• Current or recent (within previous 6 months) loss or gain of >6% of body weight
• Current or recent (<12 months) regular smoking of >5 cigarettes/day
• Alcohol intake >140 g per week for women or >210 g per week for men and/or binge drinking behaviour
• Inability or unwillingness to follow the study protocol
• Pregnancy or lactation

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Triple

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: High-nitrate (HI-NI) intervention; The 'active treatment' arm will involve daily consumption of 2×70 mL nitrate-rich (HI-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) over an intervention period of 4 weeks.	Dietary supplement: High-nitrate intervention; The 2×70 mL of nitrate-rich (i.e., 'high nitrate') beetroot juice contains 12.9 mmol nitrate (NO3-).; Other Names: HI-NI
Placebo Comparator: Low-nitrate (LO-NI) intervention; The placebo treatment arm daily consumption of 2×70 mL nitrate-depleted (LO-NI) beetroot juice (70 mL with breakfast and 70 mL with dinner) an intervention period of 4 weeks.	Dietary supplement: Low-nitrate intervention; The 2×70 mL of nitrate-depleted (i.e., 'low nitrate') beetroot juice contains 0.04 mmol (or less) nitrate.; Other Names: LO-NI

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in forearm blood flow (FBF) response to acetylcholine	Vascular function	Change from baseline FBF at 4 weeks of the HI-NI intervention
Change in forearm blood flow (FBF) response to acetylcholine	Vascular function	Change from baseline FBF at 4 weeks of the LO-NI intervention
Change in 24 hour-ambulatory systolic blood pressure	Blood pressure	Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the HI-NI intervention
Change in 24 hour-ambulatory systolic blood pressure	Blood pressure	Change from baseline 24 hour-ambulatory systolic blood pressure at 4 weeks of the LO-NI intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in granulocyte CD11b expression	Vascular inflammation biomarker	Change from baseline granulocyte CD11b expression at 4 weeks of the HI-NI intervention
Change in granulocyte CD11b expression	Vascular inflammation biomarker	Change from baseline granulocyte CD11b expression at 4 weeks of the LO-NI intervention
Change in forearm blood flow (FBF) response to glyceryltrinitrate	Vascular function	Change from baseline FBF at 4 weeks of the HI-NI intervention
Change in forearm blood flow (FBF) response to glyceryltrinitrate	Vascular function	Change from baseline FBF at 4 weeks of the LO-NI intervention

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in clinical blood pressure	Blood pressure	Change from baseline clinical blood pressure at 4 weeks of the HI-NI intervention
Change in clinical blood pressure	Blood pressure	Change from baseline clinical blood pressure at 4 weeks of the LO-NI intervention
Change in plasma nitrate and nitrite	Marker for nitrate bioavailability and functioning of the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway	Change from baseline plasma nitrate and nitrite at 4 weeks of the HI-NI intervention
Change in plasma nitrate and nitrite	Marker for nitrate bioavailability and functioning of the enterosalivary nitrate-nitrite-nitric oxide (NO) pathway	Change from baseline plasma nitrate and nitrite at 4 weeks of the LO-NI intervention
Change in blood monocyte-platelet aggregation	Vascular inflammation biomarker	Change from baseline blood monocyte-platelet aggregation at 4 weeks of the HI-NI intervention
Change in blood monocyte-platelet aggregation	Vascular inflammation biomarker	Change from baseline blood monocyte-platelet aggregation at 4 weeks of the LO-NI intervention
Change in high-sensitive plasma C-reactive protein (hsCRP)	Inflammation biomarker	Change from baseline plasma hsCRP at 4 weeks of the HI-NI intervention
Change in high-sensitive plasma C-reactive protein (hsCRP)	Inflammation biomarker	Change from baseline plasma hsCRP at 4 weeks of the LO-NI intervention

Collaborators and Investigators

• Sponsor: University of Vienna
• Collaborators: Medical University of Vienna; Flinders University; Queensland University of Technology; Edith Cowan University
• Investigators: Principal Investigator: Oliver Neubauer, Dr PhD, PD, University of Vienna

Publications and helpful links

General Publications

• Raubenheimer K, Hickey D, Leveritt M, Fassett R, Ortiz de Zevallos Munoz J, Allen JD, Briskey D, Parker TJ, Kerr G, Peake JM, Pecheniuk NM, Neubauer O. Acute Effects of Nitrate-Rich Beetroot Juice on Blood Pressure, Hemostasis and Vascular Inflammation Markers in Healthy Older Adults: A Randomized, Placebo-Controlled Crossover Study. Nutrients. 2017 Nov 22;9(11):1270. doi: 10.3390/nu9111270.
• Raubenheimer K, Bondonno C, Blekkenhorst L, Wagner KH, Peake JM, Neubauer O. Effects of dietary nitrate on inflammation and immune function, and implications for cardiovascular health. Nutr Rev. 2019 May 30:nuz025. doi: 10.1093/nutrit/nuz025. Online ahead of print.
• Blekkenhorst LC, Bondonno NP, Liu AH, Ward NC, Prince RL, Lewis JR, Devine A, Croft KD, Hodgson JM, Bondonno CP. Nitrate, the oral microbiome, and cardiovascular health: a systematic literature review of human and animal studies. Am J Clin Nutr. 2018 Apr 1;107(4):504-522. doi: 10.1093/ajcn/nqx046.

Study record dates

Study Major Dates

• Study Start (Actual): January 1, 2021
• Primary Completion (Actual): March 28, 2023
• Study Completion (Actual): March 28, 2023

Study Registration Dates

• First Submitted: September 29, 2020
• First Submitted That Met QC Criteria: October 5, 2020
• First Posted (Actual): October 14, 2020

Study Record Updates

• Last Update Posted (Actual): May 10, 2023
• Last Update Submitted That Met QC Criteria: May 9, 2023
• Last Verified: May 1, 2023

More Information

Terms related to this study

• Keywords: cardiovascular health; high blood pressure; dietary nitrate; vascular integrity; oral microbiome; inorganic nitrate-nitrite-nitric oxide pathway; chronic low-grade inflammation
• Additional Relevant MeSH Terms: Pathologic Processes; Inflammation
• Other Study ID Numbers: UVienna_Dietary nitrate

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES

IPD Plan Description

For long-time preservation and sharing of the research data, it is planned to use the PHAIDRA digital repository of the University of Vienna (https://phaidra.univie.ac.at). This repository enables the permanent secure storage of digital assists including open access publications and research data necessary to reproduce and to verify the results of the publications.

For all publications and other data related to this research that will be made available, all of the individual participant data collected during the trial will be de-identified.

• IPD Sharing Time Frame: The plan is to publish the findings in scientific journals and to present them at scientific meetings and to the public after the study is completed.
• IPD Sharing Access Criteria: Supporting the Open Access Policy of the University of Vienna, the PHAIDRA repository enables public access of the research data necessary to reproduce and to verify the results of publications from this research.
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; ICF; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No